NADINE CLEMO

Project Director, Apollo Therapeutics

Nadine Clemo is a Project Director at Apollo Therapeutics, a biotech originally formed in 2016 between Imperial College London, University College London and University of Cambridge and three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Johnson & Johnson Innovation). Apollo provides committed translational funding for novel therapeutics, sourced from academic research, accelerating them towards the clinic. Nadine is an industry-experienced scientist providing drug discovery expertise and leading a range of projects including small molecule inhibitors, gene and cell therapies and antibody therapeutics.

Prior to Apollo Therapeutics, Nadine trained as a cell biologist, receiving her PhD from the Colorectal Tumour biology group at the University of Bristol. After completing her PhD, she joined GSK in 2007. During her time at GSK, Nadine developed deep technical expertise validating and characterising therapeutic antibodies and peptides to support a range of Biopharmaceutical discovery programmes. Her experience covers multiple therapy areas including Immuno-inflammation, Oncology and Metabolic Diseases.